Google DeepMind’s AlphaGenome Atlas, announced on 8 September 2026, makes predicted molecular effects for roughly nine billion single-letter DNA changes available for researchers to look up. The Moonshots panel sees an opportunity to widen access and help patient groups organize research—but the path from a prediction to a treatment still runs through outcome data and experiments.
Insilico Medicine has announced first dosing in a 52-week Phase 3 trial of rentosertib for idiopathic pulmonary fibrosis. A separate analysis of 42 earlier-trial participants found younger-looking blood-protein profiles, prompting a Moonshots debate about longevity—but not establishing rejuvenation or longer life.
OpenAI says roughly 10,000 coordinating agents produced a proposed proof of breakdown in a forced three-dimensional fluid flow, with humans consolidating the work and Lean checking the formal argument. On Moonshots, Sam Altman’s call to pace progress divided the panel: was this an anticipated scientific capability, or a surprise about how quickly and cheaply it could be reached?